Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1
AssigneeICOS Corporation
InventorsEdward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
Life of this patent
Estimating the term…
Abstract
Compounds of the formula wherein: Y′ is O or S, W′ is optionally substituted, Z′ is selected from the group consisting of wherein Q′ is OR7 and R7 is C1-3alkyleneC3-8heterocycloalkyl useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
Claims2
A compound having a formula
- wherein:
- Y′ is O or S;
- W′ is
- optionally substituted with from one to four substituents selected from the group consisting of C1-6alkyl, aryl, N(R7)2, OR7, N3, CN, C(O)R7, C1-3alkylenearyl, C1-3alkyleneN(R2)2, halo, and
- Z′ is selected from the group consisting of:
- wherein:
- Q′ is OR7;
- J′ is selected from the group consisting of CR8, NR8, O, and S;
- K′ is selected from the group consisting of CR9, NR9, O, and S;
- L′ is selected from the group consisting of CR10, NR10, O, and S;
- M′ is selected from the group consisting of CR11, NR11, O, and S;
- and provided when Z′ is a six-membered ring J′, K′, L′ and M′ cannot be O or S;
- wherein:
- R7 is C1-3alkyleneC3-8heterocycloalkyl;
- R8, R9, and R10 are each independently selected from the group consisting of hydrogen, halo, optionally substituted C1-6alkyl, C2-6alkenyl, OCF3, NO2, CN, NC, N(R7)2, OR7, CO2R7, C(O)N(R7)2, C(O)R7, N(R13)C(O)R7, N(R13)C(O)OR7, N(R7)C(O)OR7, N(R7)C(O)C1-3alkyleneC(O)R7, N(R7)C(O)C1-3alkyleneC(O)OR7, N(R7)C(O)C1-3alkyleneOR7, N(R7)C(O)C1-3alkyleneNHC(O)OR7, N(R7)C(O)C1-3alkyleneSO2NR7, CF3, C1-3alkyleneN(R12)SO2aryl, C1-3alkyleneN(R12)SO2heteroaryl, C1-3alkyleneOC1-3alkylenearyl, C1-3alkyleneN(R12)C1-3alkylenearyl, C1-3alkyleneN(R12)C1-3alkyleneheteroaryl, C1-3alkyleneN(R12)C(O)R7, C1-3alkyleneN(R12)C(O)C1-3alkyleneOR2, C1-3alkyleneN(R12)C(O)aryl, C1-3alkyleneN(R12)C(O)C1-3alkyleneN(R12)2, C1-3alkyleneN(R12)C(O)heteroaryl, C1-3alkyleneOR7, and SR7, wherein R7 is as defined above;
- R11 is selected from the group consisting of hydrogen, optionally substituted C1-6alkyl, and halo;
- R12 is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, aryl, heteroaryl, C1-3alkylenearyl, and SO2C1-6alkyl, or two R12 groups are taken together to form an optionally substituted 3- to 6-membered ring;
- and
- R13 is hydrogen;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.